Researchers Develop a Novel AI Algorithm for Digital Pathology Analysis
Researchers developed a novel AI algorithm to classify lung cancer subtype based on lung tissue images from resected tumors.
Category: Lung Cancer
Lung Cancer
Latest
Lung Cancer
Latest
Community Oncologists Use Biomarker Testing Less Than Academic Clinicians
A recent report showed less than half of community oncologists used biomarker testing for lung cancer — compared to 73% of academic clinicians.
Lung Cancer
Latest
BioAffinity Automated Flow Cytometry Test Detects Lung Cancer in Sputum
The test validation trial resulted in CyPath Lung specificity of 88% and sensitivity of 82%, similar to far more invasive procedures currently used to diagnose lung cancer.
Israel Expands Non-Small Cell Lung Cancer Testing Coverage
Israeli laboratories are approved to use molecular profiling assays for NSCLC patients using Thermo Fisher Scientific’s Oncomine Comprehensive Assay Plus.
Read MoreGuardant Health, Janssen to Develop Liquid Biopsy Companion Diagnostic
The collaborators are pursuing regulatory approval of the Guardant360 CDx as a companion diagnostic for amivantamab for the treatment of NSCLC.
Read MoreNeoGenomics and Inivata Collaborate to Commercialize InVisionFirst-Lung Liquid Biopsy Test
InVisionFirst-Lung is a ctDNA next-generation sequencing liquid biopsy assay testing 37 genes relevant to the care of advanced NSCLC patients.
Read MoreArcherDx and AstraZeneca to Develop Personalized Cancer Monitoring Assays
ArcherDx plans to leverage the personalized cancer monitoring assays to develop companion diagnostics for AstraZeneca’s associated immunooncology therapies.
Read More
Multicancer Blood Test, Combined with Imaging, Shows Promise as Screen for Cancer
The blood test followed by PET-CT imaging was 99.6% specific for cancer.
Read More
Interventional Study to Evaluate Multicancer Early Detection Test
The Pathfinder study will enroll 6,200 participants to evaluate Grail’s investigational multicancer early detection test in clinical practice.
Read More
Urine Test Could Offer Early Detection of Lung Tumors
A noninvasive urine test that can detect the presence of proteins linked to lung cancer could help detect more tumors in the early stages of the disease.
Read More
Study Offers Promise for Multicancer Detection from a Single Blood Draw
Bluestar Genomics’ technology can noninvasively detect cancers and help identify the underlying biology of the disease using epigenetic markers.
Read More
Targeted Cancer Medicine Offers Hope for Neuroblastoma Treatment
Targeted cancer treatment using an ALK inhibitor in combination with a PIM1 inhibitor can increase the chances of survival of children with an unfavorable prognosis.
Read MoreT2 Biosystems Appoints Industry Veteran John Sperzel as Chief Executive Officer
T2 Biosystems has announced the appointment of diagnostics industry veteran John Sperzel as president and chief executive officer, succeeding John McDonough, who will continue with his board leadership role, serving as nonexecutive chairman.
Read More
AI Modeling Drives Genomic Profiling Similarity Score
Caris Life Sciences’ Molecular Intelligence GPS score aids in the characterization of cancer of unknown primary and atypical cases, while also identifying appropriate treatment options.
Read More
Blood Specimen Collection Device
Innovative device enhances ease of use and reduces the costs and environmental impact of blood sample collection, processing, and shipping.
Read More
Trial Demonstrates Potential of Blood Test to Reduce Late Detection of Lung Cancer
The Early Detection for Cancer of the Lung Scotland trial is believed to be the world’s largest trial for the detection of lung cancer using biomarkers.
Read MoreVeracyte Introduces Percepta Genomic Sequencing Classifier
The new genomic test is Veracyte’s first commercial product since the company signed a strategic collaboration with Johnson & Johnson Innovation.
Read More
Economic Study Reveals Ways to Improve the Cost-Benefit of Multigene Panel Sequencing for Advanced Non-Small Cell Lung Cancer
Multigene panels would deliver greater value if patients with actionable genetic mutations consistently received guided treatments.
Read More